INCYTE WKN: 896133 ISIN: US45337C1027 Kürzel: INCY Forum: Aktien Thema: Hauptdiskussion

Danke für die Info. Ich finde den Abverkauf aber echt heftig.

https://www.businesswire.com/news/home/20210922005863/en/Incyte-Announces-FDA-Approval-of-Jakafi%C2%AE-ruxolitinib-for-Treatment-of-Chronic-Graft-Versus-Host-Disease-GVHD

Hey DAKo, hängt sicher mit der gleichzeitigen Warnung zusammen: Incyte trades lower on safety warning in FDA approval for Opzelura https://seekingalpha.com/news/3742134-incyte-trades-lower-on-safety-warning-in-fda-approval-for-opzelura • Despite the FDA approval granted for Opzelura cream as a treatment of mild to moderate atopic dermatitis (AD), Incyte Corporation (NASDAQ:INCY) has lost ~2.5% in the pre-market after the regulator added a Boxed Warning to flag its safety concerns. • Opzelura is the first and only topical formulation of JAK (Janus kinase) inhibitors approved in the U.S., the company said. The treatment comes with the FDA’s JAK-class warning to indicate the risks of severe infections, higher risk of heart attack, stroke, etc. • The boxed warnings could hurt the long-term sales opportunity and cause a near-term reaction on company shares, Reuters reported quoting RBC analyst Brian Abraham. • The warning on Opzelura could reduce its uptake by about 30% in patients with the mild form of the disease, in particular, Abraham argues, citing a physician survey carried out by the firm. • The renewed safety concerns on the JAK class of drugs pressured AbbVie (NYSE:ABBV) early this month. The company manufactures JAK inhibitor Rinvoq (upadacitinib) indicated for rheumatoid arthritis in adults.

Das bekommen sie eine Zulassung und der Kurs bricht ein...kann mir das Mal jemand erklären?

Ich bin invistiert, Einkauf 69 Euro, 5k

So ruhig hier

Bin gerade eingestiegen

ist hier noch jemand investiert?chancen?danke

Hab nach den Zahlen die erste Position gekauft und gerade die zweite Position

-8% 🙈 trotz guten zahlen?

Der Kurs zeigt in die verkehrte Richtung 😭

Incyte Corp. übertrifft im vierten Quartal mit einem Gewinn je Aktie von $0,93 die Analystenschätzungen von $0,75. Umsatz mit $789,51 Mio. über den Erwartungen von $662,94 Mio. Quelle: Guidants News: 09.02.21, 13:20

Incyte Announces Acceptance and Priority Review of BLA for Retifanlimab as a Potential Treatment for Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) https://investor.incyte.com/press-releases/press-releases/2021/Incyte-Announces-Acceptance-and-Priority-Review-of-BLA-for-Retifanlimab-as-a-Potential-Treatment-for-Patients-with-Squamous-Cell-Carcinoma-of-the-Anal-Canal-SCAC/default.aspx

Geht da heute was ?

https://www.businesswire.com/news/home/20201207005129/en/Incyte-Announces-Parsaclisib-Treatment-Results-in-High-Rate-of-Rapid-and-Durable-Responses-in-Patients-with-Relapsed-or-Refractory-B-Cell-Non-Hodgkin-Lymphomas

Incyte EPS misses by $0.53, misses on revenue https://seekingalpha.com/news/3631986-incyte-eps-misses-0_53-misses-on-revenue Incyte (NASDAQ:INCY): Q3 Non-GAAP EPS of $0.23 misses by $0.53; GAAP EPS of -$0.07 misses by $0.57. Revenue of $620.64M (+12.5% Y/Y) misses by $1.84M.